Alexander Burik, Author at Labiotech.eu

About

Born in Chicago, I grew up close to Frankfurt, Germany. I hold an MSc in Neuroscience from University College London and a BA in Biochemistry from Knox College in the US.
Outside of science-related activities, I enjoy skiing and writing music.

Articles by Alexander Burik

News and Trends 9 Aug 2018

Modulating the Microbiome Could Boost Vaccine Performance

Dutch scientists have found that altering a patient’s microbiome with antibiotics before a vaccination can boost the body’s resulting immune response against rotavirus infection. Rotavirus causes severe vomiting and diarrhea and largely affects children. Over 200,000 children are killed by the virus each year. The rotavirus vaccine is made of weakened strains of the rotavirus, […]

August 9, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 7 Aug 2018

First 3D Placenta Model Helps Study Pregnancy Disorders

Austrian researchers have created a miniature 3D model of the human placenta, which could help us understand the causes of pregnancy complications. The human placenta plays a vital role in maintaining a healthy pregnancy, supplying the fetus with the nutrients and hormones it needs to grow and protecting it from bacterial infections. Researchers at the […]

August 7, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 7 Aug 2018

Update: Seaweed-Derived Treatment for Common Cold Approved in the EU

Update (07/08/2018): Marinomed Biotech has obtained EU approval to sell a nasal spray containing a polymer derived from red seaweed that can trap most common cold viruses to stop them from infecting us. Published on 19/07/2018 Marinomed Biotech’s antiviral treatment, which is derived from seaweed, could be used to treat the cause of respiratory […]

August 7, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Aug 2018

New Gene Therapy Could Treat Cystic Fibrosis With One Dose

A new partnership in the UK will develop a gene therapy for cystic fibrosis that could treat the disease with a single dose. Cystic fibrosis is a genetic disease that causes mucus to build up in a patient’s lungs. As a result, patients suffer from blocked airways and bacterial infections. While treatment advances have increased […]

August 6, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 3 Aug 2018

Precision Antibiotic Improves Outcome of Gut Infections in Phase II

Summit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more effective in reducing the recurrence of the disease than the standard of care. Clostridium difficile is a bacterium that can infect the gut after a patient receives broad spectrum antibiotics. C. difficile infections typically cause diarrhoea and abdominal pain, but […]

August 3, 2018 - 2 minutesmins - By Alexander Burik

Startup Scout 3 Aug 2018

This Biotech Targets the Neuronal Causes of Hearing Loss

Today, we’re in Archamps, France, visiting Pragma Therapeutics, a neuroscience biotech developing drugs to regulate neuronal signalling in hearing loss. Mission: Pragma Therapeutics develops treatments for noise-induced and age-related hearing loss that regulate glutamate levels. Glutamate is the most abundant neurotransmitter in the nervous system and makes nerve cells turn on, or fire. In patients with […]

August 3, 2018 - 2 minutesmins - By Alexander Burik

More News! 2 Aug 2018

Tomato DNA Could Help Uncover Counterfeit Breast Implants

Counterfeit breast implants can harm patients’ health and even threaten their lives. A German research team is using tomato DNA tags to tell the ‘real thing’ apart from frauds. The silicone used in implants need to have a high-quality to prevent silicone from leaking out of the implant. As a result, the silicone used in […]

August 2, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 2 Aug 2018

EMA Temporarily Scales Back Activities to Prepare for Brexit

As a result of Brexit, the European Medicines Agency will suspend some of its activities to prepare for staff cuts and its move from London to Amsterdam next year. As of October 1st, the EMA will cut back on international collaborations, developing guidelines for regulatory approval, and publishing clinical data in order to maintain its […]

August 2, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 31 Jul 2018

Recycled Forestry Waste Could Make Cosmetics, Plastics and Biofuel

An EU project is using forestry waste to make 2,3-butanediol, a chemical with a wide range of industrial applications, from perfumes to synthetic rubber and food additives. Rehap, an EU project, has found a way to produce 2,3-butanediol, a chemical building block used in a range of industrial applications, using sugars purified from forestry waste. […]

July 31, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 31 Jul 2018

Israeli Crohn’s Disease Drug Rakes in Positive Phase III Results

RedHill Biopharma has obtained positive Phase III results for its Crohn’s disease treatment, which targets a certain type of gut bacteria. Crohn’s disease is a type of inflammatory bowel disease, characterized by acute flare-ups and periods of symptom-free remission, that can affect any part of the gastrointestinal tract. It has a high prevalence for an autoimmune disease, […]

July 31, 2018 - 2 minutesmins - By Alexander Burik

More News! 30 Jul 2018

We May Soon Diagnose Traumatic Brain Injury With a Single Drop of Blood

Swiss and Spanish researchers are developing a diagnostic test that measures the severity of mild traumatic brain injury that delivers results in ten minutes with a single drop of blood. CT scans are currently the only reliable method for diagnosing mild traumatic brain injury. However, the technology is not available in all hospitals, is expensive […]

July 30, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 26 Jul 2018

Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline

The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further develop ‘oncolytic’ immunotherapies that use the herpes virus to target and attack tumor tissue. Replimune’s immunotherapies use the virus to deliver proteins into tumor tissue that help it fuse with the tumor cells. When the virus fuses to tumor cells, it activates […]

July 26, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alexander Burik

About

Articles by Alexander Burik

Modulating the Microbiome Could Boost Vaccine Performance

First 3D Placenta Model Helps Study Pregnancy Disorders

Update: Seaweed-Derived Treatment for Common Cold Approved in the EU

New Gene Therapy Could Treat Cystic Fibrosis With One Dose

Precision Antibiotic Improves Outcome of Gut Infections in Phase II

This Biotech Targets the Neuronal Causes of Hearing Loss

Tomato DNA Could Help Uncover Counterfeit Breast Implants

EMA Temporarily Scales Back Activities to Prepare for Brexit

Recycled Forestry Waste Could Make Cosmetics, Plastics and Biofuel

Israeli Crohn’s Disease Drug Rakes in Positive Phase III Results

We May Soon Diagnose Traumatic Brain Injury With a Single Drop of Blood

Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alexander Burik

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!